Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tangen Biosciences

Request full access

Portable molecular diagnostics for rapid infectious disease detection

Branford, United StatesFounded 2013Health Tech & Medtech

About Tangen Biosciences

Tangen Biosciences, Inc. is a molecular diagnostics company founded in 2013 by John Davidson and headquartered in Branford, Connecticut. The company focuses on decentralizing diagnostics by moving molecular testing from traditional laboratories to point-of-care settings like doctor's offices, pharmacies, and clinics in remote areas. The co-founders, including John Davidson (Chief Science Officer) and John Nobile, have extensive experience in developing next-generation DNA sequencing technologies at companies like Roche and Life Technologies. The leadership team was later joined by CEO Richard C. Birkmeyer, PhD, a seasoned executive with a track record of leading diagnostic startups to successful exits.

The company's core technology is the TangenDx™ platform, which consists of a portable, automated instrument called the GeneSpark™ analyzer and single-use disposable test discs. This platform utilizes isothermal nucleic acid amplification to rapidly detect targeted DNA and RNA from various patient samples, such as whole blood, swabs, and sputum, delivering results in under an hour without needing complex laboratory equipment or refrigerated reagents. A key differentiator is the system's ability to simultaneously detect a broad array of targets from a single sample with high sensitivity and a simple workflow.

Tangen Biosciences' business model centers on the development and sale of these diagnostic test kits for its platform. The company serves healthcare providers who require rapid, on-site diagnostics for infectious diseases. Its product pipeline includes tests for bloodstream infections (sepsis), respiratory viruses like SARS-CoV-2 and Influenza A/B, and antimicrobial resistance (AMR) gene panels. The firm gained significant attention during the COVID-19 pandemic, developing a point-of-care test and receiving federal contracts and an Emergency Use Authorization from the FDA. The business generates revenue through the sale of its GeneSpark instruments and the disposable assay kits. Tangen has successfully raised capital through multiple funding rounds, including a $46.6M total from investors like Connecticut Innovations, Leading Edge Ventures, and Parvizi Surgical Innovation, to scale manufacturing and accelerate clinical development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
57.9/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Diagnostics, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Aug 2020 $12M $49M Connecticut Innovations · VC23 · Leading Edge Ventures · Parvizi Surgical Innovation —
GRANT✓Other financing Apr 2020 $696K — HHS Administration for Strategic Preparedness and Response —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Tangen Biosciences website traffic

Latest recorded traffic for Tangen Biosciences is 50 monthly website visits, down 92.3% over the last three months. Tangen Biosciences's team grew 0% over the past year.

Latest monthly visits50 3-month web change-92.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tangen Biosciences in the Branford ecosystem

Live from Dealroom

The Tangen Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • HHS Administration for Strategic Preparedness and Response

Series A5 investors entered at this stage

  • Axiom Ventures
  • Connecticut Innovations
  • Leading Edge Ventures
  • VC23
  • Parvizi Surgical Innovation

Other known investors1 additional known investor

  • US Biomedical Advanced Research and Development Authority
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Branford HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tangen Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tangen Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.